SpotITearly, a biotechnology startup that uses AI and dogs to detect cancer using home testing, has announced its launch into the US market with $20 million in funding.
The company receives funding from Menomedin VC, Jeff Swartz (former CEO of Timberland), Avishai Abrahami (CEO of WIX.com), Hanaco VC and others.
Additionally, Spotietearly was awarded a grant, including one from The Bird Foundation, which funds research and development between Israeli and American companies.
The company has also announced to its board the appointment of a US-based advisor, including Dr. David Sidransky, an expert in molecular genetic cancer detection. Jonathan Fleming, lecturer at MIT and Medtech Investor. Dr. Len Lichtenfeld, former CEO of the American Cancer Society. Lichtenfeld also serves as Spotitearly’s Chief Medical Officer.
What it does
SpotItearly is a cancer screening company that uses AI and dogs to analyze volatile organic compounds in exhaled samples to detect early stage cancer.
Individuals collect breathing samples during home tests. The company will then use trained dog scent detection and clear AI technology. It analyzes thousands of data points regarding dog physical and behavioral signals to detect early stage cancer.
The test, which will be available in the US in 2026, will help detect four types of cancer: breast cancer, colorectal, prostate and lung.
The company said study About the technology published in Natureshowed a 94% accuracy rate when detecting cancer.
Spotitearly uses funds to expand its reach in the US and enhance its cancer detection technology. It also announced the opening of the Series A funding round along with launch in the US
“only 14% The US population is diagnosed with cancer through preventive screening methods. Patients have a better chance He was diagnosed with cancer in the emergency room – Clear signs of systemic issues within the health care system that are not receiving treatment prioritized over prevention,” said Shlomi Madar, CEO of Spotitearly. MobiHealthNews By email.
“By making early cancer detection and diagnosis more accessible and less invasive at a more affordable level, we can improve survival rates for millions of Americans and help move the US healthcare system from a reactive model to an aggressive model.”
Market Snapshot
One of Early research The ability to detect cancer in dogs was published in the Lancet in 1989 and called “Sniffer Dogs from Melanoma Clinic?”
More recent study“Evidence for olfactory detection in dogs with melanoma finds that “dogs can detect melanoma due to “biological or non-biological detection of volatile chemicals originating from skin lesions.”
